Home › UPDATE 1-Celgene settles U.S. patent litigation for top seller Revlimid
 

Keywords :   


UPDATE 1-Celgene settles U.S. patent litigation for top seller Revlimid

2015-12-23 01:28:35| Biotech - Topix.net

Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. The company said it would provide India-based Natco Pharma Ltd and its U.S. partner, Arrow International Limited, a unit of Allergan Plc, the license to Celgene's patents required to manufacture and market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent litigation settlement.

Tags: top update seller patent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.05Eastern North Pacific Tropical Weather Outlook
21.05Atlantic Tropical Weather Outlook
20.05Dantex USA appoints Rob Tolland VP of sales
20.05MDARD designates two bovine tuberculosis testing areas
20.05USDA moves to electronic identification tags
20.05Better pasture and hay conditions anticipated for 2024
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
More »